Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | MLNR | O43193 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | PRCP | P42785 | 3/20 | 0.36 |
| ▸ | RORC | P51449 | 3/20 | 0.36 |
| ▸ | JAK2 | O60674 | 2/20 | 0.36 |
| ▸ | JAK1 | P23458 | 2/20 | 0.36 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.35 |
| ▸ | CCR3 | P51677 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3479560 | 0.94 | MCHR1 (0.43) | MCHR1ALDH1A1TSHRNR1H2MLNR | |
| Trifluoroacetic Acid SCHEMBL3479427 | 0.90 | NR1H2 (0.35) | MCHR1ALDH1A1TSHRNR1H2BACE1 | |
| SCHEMBL3479554 | 0.84 | JAK2 (0.37) | MCHR1NR1H2BACE1JAK2JAK1 | |
| Trifluoroacetic Acid SCHEMBL3479548 | 0.78 | GPR6 (0.34) | BACE1 | |
| SCHEMBL13031015 | 0.77 | JAK2 (0.36) | ALDH1A1NR1H2MLNRBACE1JAK2 | |
| Trifluoroacetic Acid SCHEMBL3479655 | 0.77 | BACE1 (0.36) | ALDH1A1TSHRNR1H2BACE1JAK2 | |
| SCHEMBL13031022 | 0.75 | BACE1 (0.39) | ALDH1A1TSHRNR1H2BACE1JAK2 | |
| Trifluoroacetic Acid SCHEMBL3479562 | 0.75 | BACE1 (0.35) | MCHR1BACE1CCR3 | |
| SCHEMBL3479561 | 0.75 | BACE1 (0.37) | MCHR1BACE1JAK2JAK1 | |
| Trifluoroacetic Acid SCHEMBL3479483 | 0.75 | BACE1 (0.35) | NR1H2BACE1JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298342-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease | MERCK & CO., INC. (US) | 2010-11-25 | — | — | US | disclosed |
| EP-2063889-A2 | SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Merck & Co., Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008030412-A2 | SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO., INC. (US) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298342-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease | BACE1, APP, PSEN1 | MCHR1 4417/4885ALDH1A1 717/4885TSHR 4146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.